Lophius Biosciences Appoints Dr. Robert Phelps as Director Business Operations
News Dec 04, 2013
Lophius Biosciences GmbH has announced that Dr. Robert Phelps has joined the Company as Director Business Operations.
Dr. Phelps has more than thirteen years successful international experiences in business development and licensing in the biotech and pharma industry.
Lastly, he has been Head of Business Development & Licensing at SuppreMol GmbH in Munich, where he was responsible for all business development and licensing activities relating to the company’s clinical drug development candidates.
Previous to that, he has held business development and licensing positions at various biotechnology and pharmaceutical companies.
Dr. Phelps received his PhD in biochemistry from the University of Frankfurt and the Paul-Ehrlich-Institut in Germany, held a research position as a post-doctoral fellow at the Medical University of South Carolina, Charleston (SC), USA, and holds the Certified Licensing Professional (CLP) credentials.
"With his longstanding experience in business development and licensing, we are happy that we were able to get Robert on board" said Prof. Ralf Wagner, Managing Director of Lophius Biosciences. “He is a valuable addition to our team and will be instrumental in supporting our efforts to exploit the excellent development and marketing opportunities for our T cell-based diagnostic systems such as T-Track® CMV."
"I am very happy to join Lophius," Dr. Phelps added. "The Company has been highly successful in transforming their T cell monitoring platform technologies into viable products enabling doctors to individually adjust prophylactic and immunosuppressive therapy e.g. during solid organ and bone marrow transplantation to the benefit of patients. I am extremely impressed by the potential of their platform technologies and their deep product pipeline.”
Latent HIV Reservoirs Inherently Resistant to Elimination by CD8+ T-cellsNews
The latest “kick-and-kill” research to eliminate the HIV virus uncovered a potential obstacle in finding a cure. A recent study found that latent HIV reservoirs show resistance to CD8+ T-cells, a type of white blood cell whose primary function is to kill infected cells.READ MORE
LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target DiscoveryNews
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.READ MORE
Changes in Mother's Bacteria Linked to Preterm BirthsNews
Changes to the communities of microbes living in the reproductive tract of pregnant women could help to spot those at risk of giving birth prematurely. A study of hundreds of women found that subtle changes to the bacteria present in the vagina were strongly associated with the mother’s waters breaking early and preterm birth – the baby being born before 37 weeks.READ MORE